![A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness](https://push-content.springernature.io/pcf_sb_4_1510729276329136730/assets/images/Adis_logo.png "A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness"){kind=logo}
Trial Profile
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2018
At a glance
- Drugs Solriamfetol (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Jazz Pharmaceuticals Inc
- 27 Aug 2018 Status changed from active, no longer recruiting to completed.
- 29 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2018 Planned End Date changed from 1 Apr 2018 to 1 Aug 2018.